CNBC on MSN13d
Eli Lilly's Zepbound and Mounjaro are no longer in shortage. Here's where their sales still disappointedEli Lilly's blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro posted weaker-than-expected sales for the ...
Conditions are getting a bit more challenging for the drugmaker.
4don MSN
Even a juggernaut like Eli Lilly ( LLY 2.71%) can miss the mark sometimes. When it reported its third-quarter earnings on Oct. 30, its share price plunged to the tune of 11% before recovering somewhat ...
It is anticipated to reach $100 billion by 2030. Obesity drugs competing against offerings from Eli Lilly and other rivals ...
Eli Lilly announced data demonstrating more patients ... Week, held in Vienna, Austria from October 12-15. Mirikizumab is an IL23p19 antagonist that selectively binds to the p19 subunit of IL ...
The Associated Press - Business News on MSN13d
Eli Lilly’s third quarter earnings miss and forecast cut lead to sharp stock dropEli Lilly is dialing back its 2024 forecast after underwhelming Wall Street with third-quarter earnings and sales from two ...
Skyrocketing demand for weight loss and diabetes drugs has forced Eli Lilly and Novo Nordisk, to invest billions to increase ...
2monon MSN
Eli Lilly released a new form of its weight loss drug Zepbound for roughly half its usual monthly list price to increase ...
Investopedia on MSN13d
Eli Lilly Stock Tumbles as Q3 Sales, Profits Fall Well Short of EstimatesEli Lilly shares sank 10% Wednesday morning after its third-quarter results came in well below what analysts were expecting.
Eli Lilly is dialing back its 2024 forecast after underwhelming Wall Street with third-quarter earnings and sales from two key drugs that missed expectations INDIANAPOLIS -- Eli Lilly is dialing ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback